The field of cancer treatment saw a variety of advancements in 2025, from new dedicated centers to approved treatments to ...

The APP ordered a bilateral diagnostic mammogram and left breast ultrasound that revealed extremely dense breast tissue, a ...

The Phase 3 AMPLITUDE trial led by UCL found that adding the PARP inhibitor niraparib to standard hormone therapy may slow ...

The optimal approach to treatment in the post-CDK4/6 inhibitor setting remains undefined, but multiple strategies have ...

Much like finding a single sock missing after laundry day, it is easy for men to overlook the possibility of breast cancer, ...

Zydus Lifesciences has partnered with US-based Myriad Genetics to bring advanced cancer risk and prognostic tests to India, aiming to boost personalized oncology care.

Zydus partners with Myriad Genetics to introduce advanced cancer-risk assessment tests, enhancing precision diagnostics in India.

Advancements in understanding tumor biology, identifying predictive biomarkers, and developing targeted therapies have ...

Cedars Sinai gets 30M to establish a specialized BRCA cancer center focusing on research, diagnosis, and treatment in Los Angeles.

The FDA converted the PARP inhibitor's 2020 accelerated approval to full approved based on results from the Phase III TRITON3 trial.

RAD51-based assessment effectively identifies HER2-negative metastatic breast cancer patients likely to respond to olaparib, especially with BRCA1/2 or PALB2 variants. RAD51-low tumors showed a higher ...

The 85-year-old singer says that his cancer was caught early and is "gone at the moment", and is calling for others to get tested.